On April 1, the Trump administration slashed the organization that supported that research — the Agency for Healthcare ...

The FDA has approved Imfinzi (durvalumab) as neoadjuvant and adjuvant treatment in patients with muscle-invasive bladder cancer.

The study results "signal unmet needs and potentially undertreated pain in patients with cancer,” researchers wrote.

High-dose chemotherapy and HSCT can provide long-term benefits in patients with MCL, a retrospective study suggests.

Barriers to wider use of AI in oncology include inaccuracy, workflow challenges, environmental impacts, and more.

A top official at the FDA is stepping down, warning that the HHS secretary aims to spread misinformation and lies.

Though 45% of patients said they could see the benefits of AI in health care, 44% said the idea of AI in health care settings scares them.

Biomarker testing in advanced NSCLC has increased in recent years, but turnaround time has remained roughly the same, data suggest.

In a survey last year by the American Medical Association, 93% of doctors said that insurers’ prior authorization practices ...

The FDA has expanded the approval for Pluvicto (lutetium Lu 177 vipivotide tetraxetan) to include patients with PSMA-positive mCRPC who have been treated with ARPI therapy and can delay chemotherapy.

ICI-based combinations are the preferred first-line therapy due to their proven superiority over TKI monotherapy, many patients were not receiving them,” the researchers wrote.

Some patients with locally advanced esophageal cancer may be able to safely forgo esophagectomy after CRT, data suggest.